drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy (monoclonal antibody)
drug_description
Humanized, afucosylated IgG1 monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα); blocks IL-5 signaling and induces NK cell–mediated ADCC, leading to near-complete eosinophil depletion and reduced basophil activity; administered subcutaneously (e.g., 60 mg at weeks 0, 4, and 8) to suppress type 2/eosinophilic inflammation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized, afucosylated IgG1 monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα); blocks IL-5–IL-5R signaling and engages FcγRIIIa on NK cells to drive potent ADCC, leading to near-complete eosinophil depletion and reduced basophil activity, thereby suppressing type 2/eosinophilic inflammation.
drug_name
Benralizumab (Fasenra)
nct_id_drug_ref
NCT05528913